Suzhou Yongxin Biotechnology

Suzhou Yongxin Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of innovative Natural Killer (NK) cell therapies for the treatment of cancer. The company leverages its proprietary Universal NK (uNK) cell platform to produce off-the-shelf cell products that aim to overcome the limitations of traditional autologous therapies. Their pipeline includes both non-engineered NK cells and Chimeric Antigen Receptor (CAR)-engineered NK cells targeting various solid tumors and hematological malignancies. Based in the Suzhou Industrial Park, the company is focused on advancing its lead candidates through early-phase clinical trials to provide more accessible and effective immunotherapy options.